|
|
Discover how early-stage device planning—featuring task analysis, physical comparisons, and human factors studies—can help pharma partners reduce regulatory risk and strengthen ANDA submissions. |
|
|
|
Explore how a drug device developer’s pre-ANDA strategy consisting of task analysis, physical comparisons, and formative comparative use human factors studies can help support successful ANDA submissions. |
|
|
|
Learn how a drug device developer is helping pharma partners de-risk and navigate their ANDA submission with greater confidence through early-stage comparative analysis and formative human factors studies. |
|
|
|
BD Vystra™ Disposable Pen | Approved in more than 40 countries around the world, the BD Vystra™ Disposable Pen is a commercially proven solution designed for use with a wide range of fixed and variable dose therapies. | • Request Information | | |
|
|
|
|
|
